title: [Hormone replacement therapy after salpingo-oophorectomy in BRCA 1/2 mutation carriers does not increase the risk of breast cancer].
abstract: Prophylactic bilateral salpingo-oophorectomy (PBSO) reduces the risk of breast- and ovarian cancer in breast cancer gene (BRCA)1/2 mutation carriers. Women choose hormone replacement therapy (HT) to alleviate climacteric symptoms. Studies have shown a higher risk of breast cancer in healthy post-menopausal women getting HT. Further research among women with BRCA1/2 mutations is essential. No studies showed significantly that short-term use of HT alters the reduction in breast cancer risk associated with PBSO. Neither was there found any significant difference in type of HT chosen.
authors.forename: Astrid Sørbrøden
authors.initials: AS
authors.lastname: Breda
authors.affiliation: Gynækologisk-obstetrisk Afdeling, Aarhus Universitetshospital, Brendstrupgaardsvej 100, 8200 Aarhus N. jab@dadlnet.dk.
authors.forename: Jan
authors.initials: J
authors.lastname: Blaakær
mesh_terms: D001943:Breast Neoplasms / Q000139:chemically induced / Q000235:genetics / Q000517:prevention & control; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D009154:Mutation; D010051:Ovarian Neoplasms / Q000139:chemically induced / Q000235:genetics / Q000517:prevention & control; D010052:Ovariectomy; D012307:Risk Factors; D012489:Salpingostomy; D013997:Time Factors